Igea Med
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
UPDATE| In FY25A, the Group reported revenues of € 93.58 million, up 27.4% from € 73.43 million in FY24A and above our estimate of € 87.90 million. EBITDA amounted to € 20.52 million, increasing by 38.6% compared to € 14.80 million in FY24A and exceeding expectations of € 19.40 million, with an EBITDA margin of 21.9%, improving from 20.2% in the previous year. EBIT also showed a positive trend, reaching € 17.47 million (+44.2% YoY), with an EBIT margin of 18.7%, while Net Income stood at € 11.45 million, up 36.6% compared to € 8.38 million in FY24A and broadly in line with our forecasts. From a balance sheet perspective, net financial position improved significantly, moving from a cash-positive position of € 3.26 million to € 10.04 million. Following the publication of the FY25A annual report, we revise our estimates for both the current year and the medium term. Specifically, we forecast FY26E revenues at € 110.00 million and EBITDA at € 24.10 million, corresponding to a margin of 21.9%. Looking ahead, we expect revenues to increase to € 144.20 million by FY28E (CAGR 25A–28E: 15.5%), with EBITDA reaching € 32.75 million in FY28E (22.7% margin), up from € 20.52 million in FY25A (21.9% margin). From a financial standpoint, we estimate a cash-positive net financial position of € 13.89 million by FY28E. We conducted the valuation of FOPE’s equity value based on the DCF method and the multiples of a sample of comparable companies. The DCF method (which prudentially includes a specific risk of 1.0% in the WACC calculation) results in an equity value of € 279.6 million. The equity value of FOPE based on market multiples is € 263.9 million. The average equity value therefore amounts to approximately € 271.7 million. We set a target price of € 50.00, with a BUY rating and MEDIUM risk profile. |
